Involvement of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 in Ubc9-mediated resistance to chemotherapy agents

Chen,Yang; Zhang,Huixian; He,Qiyang

doi:10.3892/ijo.2016.3777

Involvement of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 in Ubc9-mediated resistance to chemotherapy agents

Authors:
- Yang Chen
- Huixian Zhang
- Qiyang He
View Affiliations

Affiliations: Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, P.R. China
Published online on: November 23, 2016 https://doi.org/10.3892/ijo.2016.3777
Pages: 223-231

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ubiquitin-conjugating protein 9 (Ubc9), the sole enzyme for sumoylation, plays critical roles in many physiological functions, such as DNA damage repair and genome integrity. Its overexpression led to poor prognosis and drug resistance in tumor chemotherapy. However, the underlying mechanism by which Ubc9 promotes tumor progress and influences the susceptibility to antitumor agents remains elusive. In this study, we used nine antitumor agents with distinct actions to explore Ubc9-mediated resistance in human breast carcinoma MCF-7 cells. Increase of susceptibility, respectively, to boningmycin, hydroxycamptothecine, cis-dichlorodiamineplatinum, 5-fluorouracil, vepeside and gemcitabine, but not for doxorubicin, vincristine and norcantharidin, was observed after the knockdown of Ubc9 protein level with RNA interference. Reduction of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 levels after knockdown of Ubc9 suggests their contribution to Ubc9-mediated drug resistance. This is the first report on the sensitivity to hydroxycamptothecine, cis-dichlorodiamineplatinum and gemcitabine that increased after knockdown of bleomycin hydrolase at protein level. In conclusion, Ubc9 plays different roles of action in antitumor agents in chemotherapy. The process requires bleomycin hydrolase and poly(ADP-ribose) polymerase-1. The results are beneficial to deeply understanding of Ubc9 functions and for precise prediction of chemotherapy outcomes in tumors.

View Figures

View References

1	Gareau JR and Lima CD: The SUMO pathway: Emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol. 11:861–871. 2010. View Article : Google Scholar : PubMed/NCBI
2	Schwertman P, Bekker-Jensen S and Mailand N: Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers. Nat Rev Mol Cell Biol. 17:379–394. 2016. View Article : Google Scholar : PubMed/NCBI
3	Stankovic-Valentin N, Drzewicka K, König C, Schiebel E and Melchior F: Redox regulation of SUMO enzymes is required for ATM activity and survival in oxidative stress. EMBO J. 35:1312–1329. 2016. View Article : Google Scholar : PubMed/NCBI
4	Guervilly JH, Takedachi A, Naim V, Scaglione S, Chawhan C, Lovera Y, Despras E, Kuraoka I, Kannouche P, Rosselli F, et al: The SLX4 complex is a SUMO E3 ligase that impacts on replication stress outcome and genome stability. Mol Cell. 57:123–137. 2015. View Article : Google Scholar
5	Ouyang J, Garner E, Hallet A, Nguyen HD, Rickman KA, Gill G, Smogorzewska A and Zou L: Noncovalent interactions with SUMO and ubiquitin orchestrate distinct functions of the SLX4 complex in genome maintenance. Mol Cell. 57:108–122. 2015. View Article : Google Scholar
6	Gupta MK, McLendon PM, Gulick J, James J, Khalili K and Robbins J: UBC9-mediated sumoylation favorably impacts cardiac function in compromised hearts. Circ Res. 118:1894–1905. 2016. View Article : Google Scholar : PubMed/NCBI
7	Klug H, Xaver M, Chaugule VK, Koidl S, Mittler G, Klein F and Pichler A: Ubc9 sumoylation controls SUMO chain formation and meiotic synapsis in Saccharomyces cerevisiae. Mol Cell. 50:625–636. 2013. View Article : Google Scholar : PubMed/NCBI
8	Mattoscio D and Chiocca S: SUMO pathway components as possible cancer biomarkers. Future Oncol. 11:1599–1610. 2015. View Article : Google Scholar : PubMed/NCBI
9	Mo YY, Yu Y, Theodosiou E, Ee PL and Beck WT: A role for Ubc9 in tumorigenesis. Oncogene. 24:2677–2683. 2005. View Article : Google Scholar : PubMed/NCBI
10	Moschos SJ, Smith AP, Mandic M, Athanassiou C, Watson-Hurst K, Jukic DM, Edington HD, Kirkwood JM and Becker D: SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: Identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene. 26:4216–4225. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ronen O, Malone JP, Kay P, Bivens C, Hall K, Paruchuri LP, Mo YY, Robbins KT and Ran S: Expression of a novel marker, Ubc9, in squamous cell carcinoma of the head and neck. Head Neck. 31:845–855. 2009. View Article : Google Scholar : PubMed/NCBI
12	Moschos SJ, Jukic DM, Athanassiou C, Bhargava R, Dacic S, Wang X, Kuan SF, Fayewicz SL, Galambos C, Acquafondata M, et al: Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum Pathol. 41:1286–1298. 2010. View Article : Google Scholar : PubMed/NCBI
13	Li H, Niu H, Peng Y, Wang J and He P: Ubc9 promotes invasion and metastasis of lung cancer cells. Oncol Rep. 29:1588–1594. 2013.PubMed/NCBI
14	Synowiec E, Krupa R, Morawiec Z, Wasylecka M, Dziki L, Morawiec J, Blasiak J and Wozniak K: Efficacy of DNA double-strand breaks repair in breast cancer is decreased in carriers of the variant allele of the UBC9 gene c. 73G>A polymorphism. Mutat Res. 694:31–38. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zhu S, Sachdeva M, Wu F, Lu Z and Mo YY: Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene. 29:1763–1772. 2010. View Article : Google Scholar :
16	Mo YY, Yu Y, Ee PL and Beck WT: Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs. Cancer Res. 64:2793–2798. 2004. View Article : Google Scholar : PubMed/NCBI
17	Lu Z, Wu H and Mo YY: Regulation of bcl-2 expression by Ubc9. Exp Cell Res. 312:1865–1875. 2006. View Article : Google Scholar : PubMed/NCBI
18	Chen SF, Gong C, Luo M, Yao HR, Zeng YJ and Su FX: Ubc9 expression predicts chemoresistance in breast cancer. Chin J Cancer. 30:638–644. 2011. View Article : Google Scholar : PubMed/NCBI
19	Mo YY, Yu Y, Shen Z and Beck WT: Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J Biol Chem. 277:2958–2964. 2002. View Article : Google Scholar
20	Han JY, Lee GK, Yoo SY, Yoon SJ, Cho EY, Kim HT and Lee JS: Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. Pharmacogenomics J. 10:86–93. 2010. View Article : Google Scholar
21	Masson M, Menissier-de Murcia J, Mattei MG, de Murcia G and Niedergang CP: Poly(ADP-ribose) polymerase interacts with a novel human ubiquitin conjugating enzyme: hUbc9. Gene. 190:287–296. 1997. View Article : Google Scholar : PubMed/NCBI
22	Koldamova RP, Lefterov IM, DiSabella MT and Lazo JS: An evolutionarily conserved cysteine protease, human bleomycin hydrolase, binds to the human homologue of ubiquitin-conjugating enzyme 9. Mol Pharmacol. 54:954–961. 1998.PubMed/NCBI
23	Schwartz DR, Homanics GE, Hoyt DG, Klein E, Abernethy J and Lazo JS: The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance. Proc Natl Acad Sci USA. 96:4680–4685. 1999. View Article : Google Scholar : PubMed/NCBI
24	Chen J, Chen Y and He Q: Action of bleomycin is affected by bleomycin hydrolase but not by caveolin-1. Int J Oncol. 41:2245–2252. 2012.PubMed/NCBI
25	Pellegrino S and Altmeyer M: Interplay between ubiquitin, SUMO, and poly(ADP-Ribose) in the cellular response to genotoxic stress. Front Genet. 7:632016. View Article : Google Scholar : PubMed/NCBI
26	Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 366:1382–1392. 2012. View Article : Google Scholar : PubMed/NCBI
27	Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15:852–861. 2014. View Article : Google Scholar : PubMed/NCBI
28	Chen Y, Xu R, Chen J, Li X and He Q: Cleavage of bleomycin hydrolase by caspase-3 during apoptosis. Oncol Rep. 30:939–944. 2013.PubMed/NCBI
29	Dieckhoff P, Bolte M, Sancak Y, Braus GH and Irniger S: Smt3/SUMO and Ubc9 are required for efficient APC/C-mediated proteolysis in budding yeast. Mol Microbiol. 51:1375–1387. 2004. View Article : Google Scholar : PubMed/NCBI
30	Tomasi ML, Tomasi I, Ramani K, Pascale RM, Xu J, Giordano P, Mato JM and Lu SC: S-adenosyl methionine regulates ubiquitin-conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers. Hepatology. 56:982–993. 2012. View Article : Google Scholar : PubMed/NCBI
31	Gao N, Shang B, Zhang X, Shen C, Xu R, Xu H, Chen R and He Q: Potent antitumor actions of the new antibiotic boningmycin through induction of apoptosis and cellular senescence. Anticancer Drugs. 22:166–175. 2011. View Article : Google Scholar
32	Huang RY, Kowalski D, Minderman H, Gandhi N and Johnson ES: Small ubiquitin-related modifier pathway is a major determinant of doxorubicin cytotoxicity in Saccharomyces cerevisiae. Cancer Res. 67:765–772. 2007. View Article : Google Scholar : PubMed/NCBI
33	Hu Y and Parvin JD: Small ubiquitin-like modifier (SUMO) isoforms and conjugation-independent function in DNA double-strand break repair pathways. J Biol Chem. 289:21289–21295. 2014. View Article : Google Scholar : PubMed/NCBI
34	Towne CF, York IA, Watkin LB, Lazo JS and Rock KL: Analysis of the role of bleomycin hydrolase in antigen presentation and the generation of CD8 T cell responses. J Immunol. 178:6923–6930. 2007. View Article : Google Scholar : PubMed/NCBI
35	Suszynska J, Tisonczyk J, Lee HG, Smith MA and Jakubowski H: Reduced homocysteine-thiolactonase activity in Alzheimer's disease. J Alzheimers Dis. 19:1177–1183. 2010.PubMed/NCBI
36	Son ED, Kim Y, Joo KM, Kim HJ, Lee E, Nam GW, Cho EG, Noh M, Chung JH, Byun SY, et al: Skin dryness in apparently healthy human skin is associated with decreased expression of bleomycin hydrolase in the stratum corneum. Clin Exp Dermatol. 40:247–253. 2015. View Article : Google Scholar
37	Zimny J, Sikora M, Guranowski A and Jakubowski H: Protective mechanisms against homocysteine toxicity: The role of bleomycin hydrolase. J Biol Chem. 281:22485–22492. 2006. View Article : Google Scholar : PubMed/NCBI
38	Borowczyk K, Tisończyk J and Jakubowski H: Metabolism and neurotoxicity of homocysteine thiolactone in mice: Protective role of bleomycin hydrolase. Amino Acids. 43:1339–1348. 2012. View Article : Google Scholar : PubMed/NCBI
39	Messner S, Schuermann D, Altmeyer M, Kassner I, Schmidt D, Schär P, Müller S and Hottiger MO: Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function. FASEB J. 23:3978–3989. 2009. View Article : Google Scholar : PubMed/NCBI
40	Zilio N, Williamson CT, Eustermann S, Shah R, West SC, Neuhaus D and Ulrich HD: DNA-dependent SUMO modification of PARP-1. DNA Repair (Amst). 12:761–773. 2013. View Article : Google Scholar
41	Scott CL, Swisher EM and Kaufmann SH: Poly (ADP-ribose) polymerase inhibitors: Recent advances and future development. J Clin Oncol. 33:1397–1406. 2015. View Article : Google Scholar : PubMed/NCBI
42	Yu B, Swatkoski S, Holly A, Lee LC, Giroux V, Lee CS, Hsu D, Smith JL, Yuen G, Yue J, et al: Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proc Natl Acad Sci USA. 112:E1724–E1733. 2015. View Article : Google Scholar : PubMed/NCBI
43	Lin CH, Liu SY and Lee EH: SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1. Oncogene. 35:595–607. 2016. View Article : Google Scholar
44	Ying S, Dünnebier T, Si J and Hamann U: Estrogen receptor alpha and nuclear factor Y coordinately regulate the transcription of the SUMO-conjugating UBC9 gene in MCF-7 breast cancer cells. PLoS One. 8:e756952013. View Article : Google Scholar : PubMed/NCBI
45	Hirohama M, Kumar A, Fukuda I, Matsuoka S, Igarashi Y, Saitoh H, Takagi M, Shin-ya K, Honda K, Kondoh Y, et al: Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2. ACS Chem Biol. 8:2635–2642. 2013. View Article : Google Scholar : PubMed/NCBI